DaVita HealthCare Partners Inc (DVA): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

DaVita HealthCare Partners ( DVA) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole was unchanged today. By the end of trading, DaVita HealthCare Partners rose $2.08 (1.9%) to $109.07 on average volume. Throughout the day, 1.2 million shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 1.1 million shares. The stock ranged in a price between $107.16-$110.13 after having opened the day at $108.29 as compared to the previous trading day's close of $106.99. Other companies within the Health Care sector that increased today were: Cardiome Pharma Corporation ( CRME), up 32.8%, Alimera ( ALIM), up 29.1%, Stereotaxis ( STXS), up 20%, and Theratechnologies ( THER), up 19.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $10.25 billion and is part of the health services industry. The company has a P/E ratio of 19.5, above the S&P 500 P/E ratio of 17.7. Shares are up 41.7% year to date as of the close of trading on Thursday. Currently there are nine analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, growth in earnings per share, increase in net income and solid stock price performance. We feel these strengths outweigh the fact that the company shows low profit margins.

On the negative front, Ariad Pharmaceuticals ( ARIA), down 20.7%, Lpath ( LPTN), down 18.8%, MEI Pharma ( MEIP), down 18.8%, and Novogen ( NVGN), down 18.4%, were all laggards within the health care sector with Life Technologies ( LIFE) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.